Tibotec Pharmaceuticals Announces Agreement to Develop and Commercialize a New Fixed-Dose Combination of TMC278 and Truvada(R) With Gilead Sciences

CORK, Ireland, July 16 /PRNewswire/ --Tibotec Pharmaceuticals today announced that it has entered into a license and collaboration agreement with Gilead Sciences, Inc. for the development and commercialization of a new once-daily fixed-dose antiretroviral product containing Tibotec's inv...

U.S. Patent Office Rejects Key HIV/AIDS Drug Patents at PUBPAT Request: Government Finds Prior Art Submitted By PUBPAT Invalidates All of Gilead Sciences' Claims

NEW YORK, Jan. 23 /PRNewswire-USNewswire/ -- The Public Patent Foundation ("PUBPAT") announced today that the U.S. Patent & Trademark Office has rejected four key HIV/AIDS drug patents held by Gilead Sciences that relate to the drug known generically as tenofovir disoproxil fumarate (TDF), a k...

Bristol-Myers Squibb and Gilead Sciences Expand Their Alliance to Include Commercialization of ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) in Europe

PRINCETON, N.J. and FOSTER CITY, Calif., Dec. 11 /PRNewswire-FirstCall/ -- Bristol-Myers Squibb Company (NYSE: BMY ) and Gilead Sciences, Inc. (Nasdaq: GILD ) today announced an agreement to commercialize ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg)...

Data from Preclinical Studies of Gilead Nucleotide Compound GS 9219 to be Presented at AACR

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mar 15, 2007 - Gilead Sciences, Inc. (Nasdaq:GILD) today announced that the company will present data on a novel nucleotide analog, GS 9219, which has shown evidence of anti-cancer activity in preclinical studies, at the 2007 Annual Meeting of the American Asso...

Schering-Plough Expands Vicriviroc Phase II Study in Treatment-Naive Patients With HIV

...b Company prescription medicine. Please see the atazanavir product insert for information on this product. 3 Truvada is a registered trademark of gilead Sciences, Inc. Please see the Truvada product insert for information on this product. 4 Hammer SM, Schechter M, Montaner JS, et al. Treatment for...

Analysis of Long-Term Vicriviroc Data Provides Evidence of Sustained Viral Suppression, Increased CD4 Cell Counts and Tolerability in Treatment-Experienced HIV-Infected Patients

...bb Company prescription medicine. Please see the atazanavir product insert for information on this product. (7) Truvada is a registered trademark of gilead Sciences, Inc. Please see the Truvada product insert for information on this product. (8) Data collection on adverse events of anti-HIV drugs (DAD) ...

Idenix Pharmaceuticals Announces Completion of Proof-of-Concept Study for IDX899 in Treatment-Naive HIV-Infected Patients

... trademark of F. Hoffman-La Roche Ltd. Reyataz(R) is a registered trademark of Bristol-Myers Squibb Company. Truvada(R) is a registered trademark of gilead Sciences, Inc. Idenix Pharmaceuticals Contacts: Amy Sullivan 617-995-9838 (investors) Teri Dahlman 617-995-9905 (media) ...

Pharmasset Announces Initiation of Combination Study of Clevudine and Viread(R) for HBV by French National Agency for Research on AIDS and Viral Hepatitis (ANRS)

...Hepatitis (ANRS), with the support of Pharmasset, Inc. (Nasdaq: VRUS ) and gilead Sciences, Inc. (Nasdaq: GILD ), has initiated the first head-to-head study... and Exchange Commission. Viread and Hepsera are registered trademarks of gilead Sciences, Inc. ...

Schering-Plough Initiates Phase II Study With Vicriviroc in Treatment-Naive HIV-Infected Patients

...ompany prescription medicine. Please see the atazanavir product insert for information on this product. 3 Truvada is a registered trademark of gilead Sciences, Inc. Please see the Truvada product insert for information on this product. 4 Vicriviroc, a next generation CCR5 antagonist, exhibits p...

Parion Sciences Announces Phase I Clinical Results for Novel Dry Mouth Treatment

...a Phase I clinical trial in Sjogren's syndrome and a Phase II clinical trial in cystic fibrosis. In August 2007, Parion announced a collaboration with gilead Sciences focused on developing drug candidates for pulmonary diseases utilizing Parion's expertise in epithelial sodium channel blockers. Parion was f...

Microbicide Developer Receives License for Novel HIV Microbicide Candidate From Merck & Co., Inc.

... 2008 agreed to allow IPM to develop the CCR5 blocker maraviroc as a microbicide. In December 2006, IPM and CONRAD reached independent agreements with gilead Sciences to develop tenofovir (PMPA), a nucleoside reverse transcriptase inhibitor. In October 2005, IPM entered agreements with Merck and Bristol-Mye...

European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection

...int Venture Between Bristol-Myers Squibb and gilead Sciences, the First of Its Kind in HIV Treatment -...enofovir disoproxil fumarate are commercialized by gilead Sciences, Inc. (Nasdaq: GILD) under the tradenames...nture based in Ireland called Bristol-Myers Squibb gilead Sciences And Merck Sharp & Dohme Limited. ATRIPL...

Chimerix Initiates a Multi-dose Clinical Trial of the Company's Lead Compound, CMX001, for the Treatment for Smallpox Infection

...rovided excellent drug exposure and were well tolerated in healthy volunteers. CMX001 is being developed for smallpox under a licensing agreement with gilead Sciences, Inc. The work is partially funded by a $36.1 million grant awarded to the company by the National Institutes of Allergy and Infectious Disea...

PARI's eFlow Included in Gilead's NDA Submission for Aztreonam Lysine for Inhalation

... symptoms and prevent further lung damage. About gilead Sciences gilead Sciences is a biopharmaceutical company that disco...al need. Headquartered in Foster City, California, gilead has operations in North America, Europe and Austra...

European CHMP Issues Positive Opinion for ATRIPLA(R) (efavirenz 600 mg/ emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg)

...enofovir disoproxil fumarate are commercialized by gilead under the tradenames Emtriva(R) and Viread(R), res...nture based in Ireland called Bristol-Myers Squibb gilead Sciences And Merck Sharp & Dohme Limited. ATRIPLA...ly available in the United States. In August 2006, gilead and Merck established an agreement for distributio...

Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV

...enture Between Bristol-Myers Squibb Company and gilead Sciences, the First of Its Kind in HIV Treatment -... -- Bristol-Myers Squibb Company (NYSE: BMY ) and gilead Sciences, Inc. (Nasdaq: GILD ) announced today th...ne/tenofovir disoproxil fumarate), manufactured by gilead Sciences. Truvada itself is a fixed-dose product t...

Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV

...d for the treatment of HIV in combination with other approved HIV drugs, has completed a Phase 2 clinical trial. Hepsera is a registered trademark of gilead Sciences, Inc. Contact Alan Roemer, Vice President Investor Relations & Corporate Communications alan.roemer@pharmasset.com Office: (609) 613-...

BiPar Expands Management Team to Advance Lead PARP Inhibitor Product Candidate Into Phase 2 Trials for Cancer

... in peripheral T-cell lymphoma, and RH1, currently in a Phase 1 trial for solid tumors. Before Allos, Mr. Malek held business development positions at gilead Sciences, Inc., NeXstar Pharmaceuticals, Ilex Oncology, Inc. and Research Corporation Technologies. He has an undergraduate degree in biochemistry fro...

New Phase 3 Study in Treatment-Naive Adults with HIV Evaluates Efficacy and Safety of Once-Daily PREZISTA(TM)/ritonavir vs. KALETRA(R) as Part of HIV Combination Therapy

...sult of new information or future events or developments. 1. Truvada(R) (emtricitabine and tenofovir disoproxil fumarate) is a trademark owned by gilead Sciences, Inc. 2. Kaletra(R) (lopinavir/ritonavir) is a trademark owned by Abbott Laboratories Contacts: Pam Van Houten Office: (908) 541-413...

Merck/Gilead Once-A-Day AIDS Pill Not Available in Most Places - AHF Urges Speed-Up of Registrations

... greatly increase effectiveness for patients, but gilead Sciences and Merck and Co. have failed to register...- AIDS Healthcare Foundation (AHF) today called on gilead Sciences and Merck to immediately register and dis...DS Healthcare Foundation President. "The fact that gilead and Merck appear to be unable or unwilling to make...

Promising Cystic Fibrosis Compound on Track for Development

... BETHESDA, Md., Aug. 15 /PRNewswire-USNewswire/ -- gilead Sciences, Inc., one of the world's largest biophar...is promising therapy moving forward," said Beall. gilead Sciences, through the purchase of Corus Pharmaceut...ne to the FDA by the end of 2007. In the meantime, gilead recently announced it has made available an early ...

Achillion Presents Positive Data on Novel Mechanism for Treating HCV at EASL Annual Meeting

...collaboration and exclusive license agreement with gilead Sciences for the research, development and commerc... HCV," said Dr. Pottage. "While we and our partner gilead decided to discontinue development of ACH-806 base...get and therefore supports our continued work with gilead to identify and evaluate next-generation compounds...

Gilead Announces Presentation of Positive Phase III Data on Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis

... SEATTLE--(BUSINESS WIRE)--Apr 19, 2007 - gilead Sciences, Inc. (Nasdaq:GILD) today announced detai... Vice President, Head of Respiratory Therapeutics, gilead Sciences. "These comprehensive findings provide va...ceived in AIR-CF1 or AIR-CF2 (BID or TID daily). gilead anticipates that data from AIR-CF1 will be availab...

Gilead Announces Presentation of Long-Term Data for Ambrisentan, a Potential Treatment for Patients With Pulmonary Arterial Hypertension

... SAN FRANCISCO--(BUSINESS WIRE)--May 21, 2007 - gilead Sciences, Inc. (Nasdaq:GILD) today announced resul... approximately 200,000 patients worldwide. About gilead Sciences gilead Sciences is a biopharmaceutical company that disco...

Gilead Announces Achievement of Primary Efficacy Endpoint in Second Phase III Study of Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis

... symptoms and prevent further lung damage. About gilead Sciences gilead Sciences is a biopharmaceutical company that disco...rldwide. Headquartered in Foster City, California, gilead has operations in North America, Europe and Austra...

Diatos Announces Positive Clinical Results for its DTS-201 Doxorubicin Prodrug Program

...ormulations. DaunoXome is marketed in Kaposi's sarcoma and under review for the treatment of acute leukaemia in Europe. DaunoXome was in-licensed from gilead Sciences, Inc. (NASDAQ: GILD). -- DTS-301, a paclitaxel depot formulation in the polymer gel ReGel(R), releases paclitaxel, a widely used cancer dru...

Phase III Study Evaluating Gilead's Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint

...k Rousseau, MD, Vice President, Clinical Research, gilead Sciences. "We believe Viread has the potential to ...le for download online at www.hepsera.com. About gilead Sciences gilead Sciences is a biopharmaceutical company that disco...

Second Phase III Study Evaluating Gilead's Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint

...k Rousseau, MD, Vice President, Clinical Research, gilead Sciences. "We look forward to reviewing these data...le for download online at www.hepsera.com. About gilead Sciences gilead Sciences is a biopharmaceutical company that disco...

Second Phase III Study Evaluating Gilead's Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint

...k Rousseau, MD, Vice President, Clinical Research, gilead Sciences. "We look forward to reviewing these data...http://www.hepsera.com/">www.hepsera.com . About gilead Sciences gilead Sciences is a biopharmaceutical company that disco...